#Tetrous #EnFix #orthopedic

Tetrous, Inc. Achieves New Milestone with Patent Grant

Tetrous, Inc., a promising startup based in Sherman Oaks, has taken a significant step in the field of orthopedic surgery by securing a new patent from the United States Patent and Trademark Office. This marks the sixth patent issued for their innovative EnFix DBF (demineralized bone fiber) technology, aimed specifically at enhancing the healing process between bone and tendon tissues after surgery.

The latest patent protects the manufacturing process and applications of EnFix DBF implants, showcasing Tetrous's dedication to advancing medical interventions for sports injuries. According to Andy Carter, PhD, co-founder and Chief Technology Officer, this patent underscores the company’s commitment to innovate and expand clinical applications of their proprietary technology designed for enthesis repair.

What is Enthesis Failure Syndrome?

Enthesis Failure Syndrome, characterized by the insufficient healing at the junction where tendons attach to bones, is recognized as a prevalent hurdle in sports medicine practices. With this new patent, Tetrous aims to address this widespread issue, illustrating their focus on clinically pertinent innovations in orthopedic treatment.

The EnFix DBF technology is engineered to promote essential biological healing properties, such as osteoinductivity and osteoconductivity, thereby enhancing the overall healing process while being compatible with standard surgical procedures. This capability is particularly vital in achieving successful results where biological integration and fixation strength significantly influence recovery outcomes.

The Growing Demand for Biologic Solutions

In recent years, there has been an uptick in interest regarding biologic solutions for ligament and tendon repairs, further emphasizing the importance of Tetrous’s patented technology. As John Bojanowski, Chief Commercial Officer of Tetrous, notes, despite advances in surgical techniques and instruments, achieving biologic healing in joint repairs remains a challenge. **“Our EnFix DBF products have the potential to revolutionize treatment standards in various sports medicine injuries,